Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology

Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain. Seven pharma companies have been selected for the FDA PreCheck pilot – a framework intended to bolster the US drug supply chain. Developed in response to an executive order signed by President Donald Trump, the programme became the first FDA policy directed at bolstering US pharma manufacturing. Credit: IM Imagery/Shutterstock.com. Eli Lilly and Regeneron are in the first slate of drugmakers included in a new US scheme to expedite the construction of new pharmaceutical manufacturing facilities. Lilly and…

Source: Pharmaceutical Technology